Abstract Title:

Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment.

Abstract Source:

FEBS Lett. 1997 Jun 30;410(2-3):254-8. PMID: 9237640

Abstract Author(s):

A Palomäki, K Malminiemi, T Metsä-Ketelä

Article Affiliation:

Kanta-Häme Central Hospital, Hameenlinna, Finland.


A double-blinded, placebo-controlled cross-over trial was carried out with 27 hypercholesterolemic men with coronary heart disease. During the 6-week treatment period lovastatin (60 mg/day) decreased fasting serum LDL cholesterol by 45%, LDL phosphorus by 38% and apoB by 33%. Ubiquinol content diminished by 13% as measured per LDL phosphorus. When LDL was oxidized ex vivo with AMVN both LDL ubiquinol and alpha-tocopherol were exhausted faster after lovastatin treatment compared to placebo, by 24% (P<0.005) and 36% (P<0.0001), respectively. Lag time in copper-induced oxidation of LDL decreased by 7% (P<0.01). This suggests diminished antioxidant-dependent resistance of LDL to the early phase of oxidative stress.

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.